Inactive Instrument

Press Releases GlaxoSmithKline plc London S.E.

Equities

End-of-day quote London S.E. Other stock markets
- ^GBX	-

06-20	GSK : Berenberg renews its buy recommendation	CF
06-19	GSK : Deutsche Bank remains its Buy rating	ZD

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

GSK : Director/Pdmr Shareholding Form 6 K	06-21	PU
List of Companies That Allegedly Left Nigeria Under Tinubu's Presidency Is Not Accurate	06-21	AQ
HPV Vaccination Switching to Single-Dose and Private Schools to Get Government Supply	06-19	AQ
US FDA approves expanded age indication for GSK's Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk \| GSK	06-10	AQ
US FDA Approves Expanded Age Indication for GSK’s AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk	06-07	BU
GSK : DO NOT COURIER US FDA approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk	06-07	PU
GSK accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies \| GSK	06-07	AQ
GSK : accelerates oligonucleotide platform and pipeline medicines with acquisition of Elsie Biotechnologies	06-06	PU
Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer \| GSK	06-04	AQ
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer - Form 6-K	06-03	PU
Jemperli (dostarlimab-gxly) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	06-03	BU
GSK : Jemperli (dostarlimab) trial continues to show unprecedented results with no evidence of disease in 100% of patients with locally advanced mismatch repair deficient (dMMR) rectal cancer	06-03	PU
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma - Form 6-K	06-03	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling - Form 6-K	06-03	PU
Statement: Zantac (ranitidine) litigation - Delaware State Court Daubert Ruling \| GSK	06-03	AQ
Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma \| GSK	06-03	AQ
GSK : Blenrep combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma	06-02	PU
Belantamab Mafodotin combination reduced the risk of disease progression or death by nearly 50% versus standard of care combination in relapsed/refractory multiple myeloma	06-02	BU
New data at ASCO showcases the transformational potential of GSK's oncology portfolio \| GSK	05-29	AQ
Statement: Zantac (ranitidine) litigation - Valadez and Williams cases - Form 6-K	05-24	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GSK PLC : Frightened markets create an entry opportunity in GSK

June 04, 2024 at 01:38 pm

GSK plc : Back on track

May 03, 2024 at 10:17 am